NEW YORK, March 6, 2013 /PRNewswire/ --
Today, Investors Alliance announced new research reports highlighting Air Methods Corporation (NASDAQ: AIRM), Express Scripts Holding Company (NASDAQ: ESRX), Catamaran Corp (USA) (NASDAQ: CTRX), Covance Inc. (NYSE: CVD) and MedAssets, Inc. (NASDAQ: MDAS), Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Air Methods Corporation Research Report
Air Methods now provides medical communication services via its DirectCall Transfer to KentuckyOne Health's 18 hospitals and ambulatory care centers in Kentucky. Air Method assists with inter-facility patient transports between Kentucky One Health-affiliated hospitals and ambulatory care centers and non-Kentucky One Health medical centers by managing all incoming and outgoing calls between the health system's hospitals, doctors and other hospitals. According to Aaron Todd, CEO-Air Methods, the transfer center service won't just streamline KentuckyOne's patient transfer process but it will also assist in ensuring that patients remain in their system. The Full Research Report on Air Methods Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investors-alliance.com/r/full_research_report/431f_AIRM]
--
Express Scripts Holding Company Research Report
Express Scripts' SOCRxATES program combines innovative technology with specially trained community pharmacists. This program plays an important role in helping patients improve adherence to chronic therapies, as it aims to improve care for those with chronic medical conditions. The American Journal of Managed Care reported this program as a success as pharmacists in the program receiving computer alerts from Express Scripts closed nearly 10% more adherence-related gaps in care within 30 days compared to pharmacists not working with the program. It also showed that the same pharmacists were far more successful in initiating essential therapies. The Full Research Report on Express Scripts Holding Company - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investors-alliance.com/r/full_research_report/0ac9_ESRX]
--
Catamaran Corp (USA) Research Report
Catamaran Corporation, a leading provider of pharmacy benefit management services and technology posts a record setting year with a 100% increase in revenue on a year-over-year basis. The company's gross profits reached $733.4 million during 2012, compared to $309.5 million in 2011. "This past year has been a transformative period for Catamaran, led by the merger with Catalyst which doubled our size. Throughout this period, we never lost sight of our goals and operational plan, which was the foundation for the results we achieved in 2012. Our operational excellence, coupled with the successful progression of our integrations, yielded another record setting year. The dramatic changes embarked upon by Catamaran in 2012, combined with the financial savings and clinical results we delivered to our customers, have created a number of new opportunities for us," said Mark Thierer, Chairman and CEO of Catamaran. "The entire company is focused on continuing to deliver superior results, and we are well positioned to take advantage of our growth and enhanced capabilities in 2013." The Full Research Report on Catamaran Corp (USA) - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investors-alliance.com/r/full_research_report/59dd_CTRX]
--
Covance Inc. Research Report
An exclusive alliance and services agreement was sealed between Covance and M2Gen - a Moffitt Cancer center subsidiary and leader in personalized cancer treatments. The agreement will promote faster patient recruitment in biomarker-driven oncology trails by offering to match biopharmaceutical clients to potential patients. Covance will become M2Gen's preferred provider for DNA/RNA sequencing, gene expression analysis, and genotyping analysis services, which will be conducted at Covance's genomic lab in Seattle, Washington. "Working together, Covance and M2Gen expect to help biopharmaceutical companies accelerate their drug development programs, make better decisions, and improve their efforts to develop targeted therapies for cancer patients," said Ken Somberg, MD, Chief Medical Officer for Covance and Vice President, Clinical Development Services. "M2Gen's database is unique in the industry, with clinical data captured and maintained over the cancer patient's lifetime. This alliance will help us partner with sponsors as the field of personalized medicine continues to evolve, and as we work toward a common goal of bringing new life-saving medicines to patients who need them." The Full Research Report on Covance Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investors-alliance.com/r/full_research_report/7945_CVD]
--
MedAssets, Inc. Research Report
Texas' third largest public system, University Health System, has recently engaged MedAssets for a multi-year, comprehensive agreement for a sustainable, organizational transformation to eliminate inefficiencies, reduce costs and enhance revenue and performance to improve the quality and safety of care delivery. "Anticipating the negative financial impact of healthcare reform, University Health System was looking for a single, comprehensive source for a cost-effective suite of data and technology-enabled services to quickly improve our health system's clinical, operational and financial capabilities," said Christann Vasquez, Executive Vice President and CEO, University Health System. "With MedAssets, we found a true partner to help us meet the new business model of care delivery. We are excited by the positive change to date, and we look forward to continue to build upon the progress we have already accomplished." The multi-pronged agreement is based upon a holistic operational improvement and cost reduction strategy that focuses on process and cultural change in five main areas across the enterprise: clinical resource utilization, labor, purchased services, supply expense and revenue capture. Specific MedAssets solutions engaged are: Process Improvement and Clinical Consulting services, Workforce, Capital and Construction solutions, Strategic Sourcing, Reimbursement Integrity and Charge Integrity solutions. The Full Research Report on MedAssets, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investors-alliance.com/r/full_research_report/c110_MDAS]
--
Consider Investors Alliance
Tired of hearing about the latest, greatest trade opportunity... only to realize that the ship has long sailed? You need a strong, informative community in your arsenal. Join the group that has been consistently identifying momentous situations as they develop - long before they become the next top news on major financial networks.
Contact: Patricia Byers
Email: press@ investors-alliance.com
Main: +1-(408)-745-7826
SOURCE Investors-Alliance
